Skip to search formSkip to main contentSkip to account menu

GW 572016

Known as: GW-572016, GW572016 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor… 
Highly Cited
2006
Highly Cited
2006
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here… 
Review
2006
Review
2006
Objective: To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and drug interactions of lapatinib… 
Highly Cited
2005
Highly Cited
2005
PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with… 
Review
2005
Review
2005
Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy… 
Highly Cited
2005
Highly Cited
2005
Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of… 
Highly Cited
2005
Highly Cited
2005
PURPOSE This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients… 
Highly Cited
2004
Highly Cited
2004
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of… 
Highly Cited
2002
Highly Cited
2002
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR…